236 related articles for article (PubMed ID: 33152120)
1. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
Jang JH; Tomiyama Y; Miyazaki K; Nagafuji K; Usuki K; Uoshima N; Fujisaki T; Kosugi H; Matsumura I; Sasaki K; Kizaki M; Sawa M; Hidaka M; Kobayashi N; Ichikawa S; Yonemura Y; Enokitani K; Matsuda A; Ozawa K; Mitani K; Lee JW; Nakao S
Br J Haematol; 2021 Jan; 192(1):190-199. PubMed ID: 33152120
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome.
Sharathkumar A; Carr J; Claassen D; Syrbu S; Bhagavathi S; Al-Huniti A; Modi A; Bates M; Mott SL
J Pediatr Hematol Oncol; 2024 Jul; 46(5):252-261. PubMed ID: 38787686
[TBL] [Abstract][Full Text] [Related]
4. Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
Ise M; Iizuka H; Kamoda Y; Hirao M; Kida M; Usuki K
Int J Hematol; 2020 Dec; 112(6):787-794. PubMed ID: 32876852
[TBL] [Abstract][Full Text] [Related]
5. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R
Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
7. Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series.
Al-Huniti A; Rathi N; Modi A; Bhagavathi S; Mitten R; Sharathkumar AA
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e431-e435. PubMed ID: 32341259
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
9. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
10. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
12. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia.
Zhao LP; Sicre De Fontbrune F; Contejean A; Abraham J; Terriou L; Chabrot C; Charbonnier A; Lengline E; Socié G; Peffault de Latour R
Bone Marrow Transplant; 2019 Jul; 54(7):1161-1163. PubMed ID: 30670823
[No Abstract] [Full Text] [Related]
13. Romiplostim or standard of care in patients with immune thrombocytopenia.
Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
[TBL] [Abstract][Full Text] [Related]
14. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
[TBL] [Abstract][Full Text] [Related]
15. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
Gill H; Leung GM; Lopes D; Kwong YL
Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929
[No Abstract] [Full Text] [Related]
16. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
17. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
DasGupta RK; Levine L; Wiczer T; Cataland S
J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
19. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
[TBL] [Abstract][Full Text] [Related]
20. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
